Reportedly, as part of a 2007 suit, Johnson & Johnson has alleged that Boston Scientific’s Promus Everolimus-Eluting Coronary Stent System infringed these four patents, known as the Wright/Falotico patents. The patents relate to coatings (drug and polymer) for drug-eluting stents.
Ray Elliott, president and CEO of Boston Scientific, said: “We are pleased with the Court’s finding that all four Johnson & Johnson patents are invalid. Boston Scientific will continue to vigorously defend against any charges of infringement. We continue to attempt to resolve remaining outstanding matters with Johnson & Johnson.”
Boston Scientific is a manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.